The lancet oncology
-
The lancet oncology · Apr 2011
Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries.
Improvements in cancer survival have made the long-term risks from treatments more important, including the risk of developing a second cancer after radiotherapy. We aimed to estimate the proportion of second cancers attributable to radiotherapy in adults with data from the US Surveillance, Epidemiology and End Results (SEER) cancer registries. ⋯ US National Cancer Institute.
-
The lancet oncology · Apr 2011
Randomized Controlled Trial Multicenter Study Comparative StudyColonic stenting versus emergency surgery for acute left-sided malignant colonic obstruction: a multicentre randomised trial.
Colonic stenting as a bridge to elective surgery is an alternative for emergency surgery in patients with acute malignant colonic obstruction, but its benefits are uncertain. We aimed to establish whether colonic stenting has better health outcomes than does emergency surgery. ⋯ None.
-
The lancet oncology · Apr 2011
Randomized Controlled TrialMotesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.
Vascular endothelial growth factor (VEGF) has a crucial role in angiogenesis, and is a valid target in metastatic breast cancer. Motesanib is an investigational oral inhibitor of VEGF receptors. We aimed to determine whether treatment with motesanib plus paclitaxel is better than placebo plus paclitaxel in patients with HER2-negative locally recurrent or metastatic breast cancer. ⋯ Amgen.